Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Adjuvant Capecitabine in Pancreatic Cancer
NCT00854477Phase 4Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Nov 2009
- Primary completion
- Aug 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of capecitabine in pancreatic adenocarcinoma (PDAC), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Nov 2009; status: completed.
02
Drugs
capecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00854477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00854477.